Welcome to our dedicated page for Fulcrum Therapeutics SEC filings (Ticker: FULC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Fulcrum Therapeutics, Inc. filings document the regulatory record of a clinical-stage biopharmaceutical company focused on small-molecule therapies for genetically defined rare diseases and rare hematological disorders. Form 8-K reports cover operating results, financial condition, Regulation FD corporate presentations, clinical updates for pociredir in sickle cell disease, and material agreements, including license arrangements tied to development programs.
Proxy materials disclose board and governance matters, executive compensation, equity awards, shareholder voting items, and related ownership information. The filing record also documents capital-structure items such as common stock and inducement equity plans alongside public-company disclosures tied to drug development programs and collaboration agreements.
Fulcrum Therapeutics (FULC) filed an 8-K stating it announced financial results for the quarter ended September 30, 2025. A detailed press release was furnished as Exhibit 99.1 and incorporated by reference. The Item 2.02 information, including the exhibit, is furnished and not deemed filed under the Exchange Act. Fulcrum’s common stock trades on the Nasdaq Global Market under the symbol FULC.
Fulcrum Therapeutics, Inc. furnished an updated corporate presentation dated August 28, 2025 that may be used at conferences and investor meetings. The presentation is available in the Events and Presentations section of the company’s website and is attached as Exhibit 99.1. Fulcrum specifies that this material is provided under Regulation FD and is considered “furnished” rather than “filed,” which means it is not automatically subject to certain Exchange Act liabilities or incorporated into other securities law filings unless specifically referenced.
Adage Capital Management, L.P., together with Robert Atchinson and Phillip Gross, reports shared beneficial ownership of 4,589,000 shares of Fulcrum Therapeutics common stock, representing 8.50% of the class based on 53,979,306 shares outstanding. The shares are held directly by Adage Capital Partners, L.P., with Adage acting as investment manager and Messrs. Atchinson and Gross identified as managing members of the related entities.
The filing shows no sole voting or dispositive power; all voting and disposition power is reported as shared. The reporting persons certify the holdings are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.